January 16, 2018 8:42 PM ET

Pharmaceuticals

Company Overview of Intas Pharmaceuticals Limited

Company Overview

Intas Pharmaceuticals Limited engages in the manufacture, marketing, distribution, and sale of finished pharmaceutical formulations, active pharmaceutical ingredients, medical appliances, and medical devices worldwide. The company provides products in various therapeutic areas, such as neurology, psychiatry, cardiology, diabetology, urology, nephrology, and pain management. It offers a portfolio of biosimilar products across microbial and mammalian cell culture products, such as Neukine, Erykine, Intalfa, Pegasta, Terifrac, Mabtas, and Folisurge, as well as operates in the field of plasma derived products and therapies. The company also provides scientific and prescription driven therapies c...

Chinubhai Centre

Off. Nehru Bridge

Ashram Road

Ahmedabad,  380009

India

Founded in 1985

Phone:

91 79 6652 3100

Fax:

91 79 2657 8862

Key Executives for Intas Pharmaceuticals Limited

Chief Executive Officer, Managing Director and Director
Age: 56
Founder and Chairman
Age: 84
Vice Chairman, Managing Director and Executive Non Independent Director
Age: 53
Managing Director and Executive Non Independent Director
Age: 58
Chief Finance Officer
Age: 53
Compensation as of Fiscal Year 2017.

Intas Pharmaceuticals Limited Key Developments

Sanofi’s $2 Billion European Generics Business Attracts Indian Pharma Majors

Aurobindo Pharma Limited (BSE:524804), Cadila Healthcare Limited (BSE:532321), Torrent Pharmaceuticals Limited (BSE:500420) and Intas Pharmaceuticals Limited are among the companies that have expressed preliminary interest in buying the European generic business of Sanofi. The portfolio could fetch Sanofi a valuation of $1.5 to $2 billion. Pitted against these potential Indian buyers are a top Chinese drugmaker and an array of global private equity players, some of whom may tie up with strategic players. Apax Partners, Europe's leading private equity buyout shop, is joining forces with Zydus Cadila, while Intas is backed by Temasek Holdings (Private) Limited and ChrysCapital.

Intas Pharmaceuticals Limited Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-09-2018 03:00 PM

Intas Pharmaceuticals Limited Presents at 36th Annual J.P. Morgan Healthcare Conference, Jan-09-2018 03:00 PM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Gerald Price, President, Accord Healthcare.

Intas Biopharmaceuticals Presents at BioPharma India Convention 2017, Sep-19-2017 04:30 PM

Intas Biopharmaceuticals Presents at BioPharma India Convention 2017, Sep-19-2017 04:30 PM. Venue: GRAND HYATT MUMBAI, MUMBAI, Maharashtra, India. Speakers: Dinesh Kundu, General Manager, Biologics Business Strategy.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
April 5, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Intas Pharmaceuticals Limited, please visit www.intaspharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.